{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T09:17:58Z","timestamp":1742635078510},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Studies have shown that early detection and treatment of neovascular age-related macular degeneration (NV-AMD) can delay vision loss and blindness. The objective of this study was to evaluate the efficacy\/safety of intravitreal pegaptanib sodium monotherapy in treatment-na\u00efve subjects with newly diagnosed NV-AMD and to gain insight into characteristics of lesions treated in community-based practices.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From seven private US practices, charts were retrospectively reviewed on 73 subjects with previously untreated subfoveal choroidal NV-AMD treated with their first dose of pegaptanib monotherapy on\/after 4\/1\/2005 through 6\/5\/2006, receiving \u22654 treatments at 6-week intervals over 21 weeks. Primary endpoint: mean visual acuity (VA) change from baseline to month 6.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>75% of lesions were occult, and 82% were subfoveal. From baseline to month 6, mean VA change was -0.68 lines; 58% and 16% gained \u22650 and \u22653 lines of VA, and 70% were responders (&lt;3 lines lost). In 35 subjects with early disease, 80% were responders with a mean gain of 0.46 lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Pegaptanib is effective in real-world patients with treatment-na\u00efve NV-AMD in uncontrolled community-based retina practices.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2415-10-2","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T19:16:10Z","timestamp":1265742970000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study"],"prefix":"10.1186","volume":"10","author":[{"given":"Pamela A","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara M","family":"Wirostko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergana","family":"Zlateva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,9]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","volume":"48","author":"J Ambati","year":"2003","unstructured":"Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP: Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003, 48: 257-293. 10.1016\/S0039-6257(03)00030-4.","journal-title":"Surv Ophthalmol"},{"key":"162_CR2","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP: Global data on visual impairment in the year 2002. Bull World Health Organ. 2004, 82: 844-851.","journal-title":"Bull World Health Organ"},{"key":"162_CR3","unstructured":"AMD Alliance International: Facts about AMD. [http:\/\/www.amdalliance.org\/information\/basicfacts\/typesofamd.php]"},{"key":"162_CR4","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1001\/jama.288.18.2233","volume":"288","author":"MD Gottlieb","year":"2002","unstructured":"Gottlieb MD, Justin L: Age-related macular degeneration. JAMA. 2002, 288: 2233-2236. 10.1001\/jama.288.18.2233.","journal-title":"JAMA"},{"key":"162_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004, 122: 564-572. 10.1001\/archopht.122.7.1019.","journal-title":"Arch Ophthalmol"},{"key":"162_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"T Wong","year":"2008","unstructured":"Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I: The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008, 115: 116-126. 10.1016\/j.ophtha.2007.03.008.","journal-title":"Ophthalmology"},{"key":"162_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"Age-related Eye Disease Study Research Group","year":"2001","unstructured":"Age-related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report 8. Arch Ophthalmol. 2001, 119: 1417-1436.","journal-title":"Arch Ophthalmol"},{"key":"162_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(96)01440-7","volume":"348","author":"P Dargent-Molina","year":"1996","unstructured":"Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Br\u00e9art G: Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996, 348: 145-149. 10.1016\/S0140-6736(96)01440-7.","journal-title":"Lancet"},{"key":"162_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1046\/j.1532-5415.2003.51109.x","volume":"51","author":"RQ Ivers","year":"2003","unstructured":"Ivers RQ, Cumming RG, Mitchell P, Simpson JM, Peduto AJ: Visual risk factors for hip fracture in older people. J Am Geriatr Soc. 2003, 51: 356-363. 10.1046\/j.1532-5415.2003.51109.x.","journal-title":"J Am Geriatr Soc"},{"key":"162_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S0002-9394(03)00573-7","volume":"136","author":"DJ Lee","year":"2003","unstructured":"Lee DJ, G\u00f3mez-Mar\u00edn O, Lam BL, Zheng DD: Visual impairment and unintentional injury mortality: the National Health Interview Survey 1986-1994. Am J Ophthalmol. 2003, 136: 1152-1154. 10.1016\/S0002-9394(03)00573-7.","journal-title":"Am J Ophthalmol"},{"key":"162_CR11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/bjo.2007.116939","volume":"91","author":"A Lotery","year":"2007","unstructured":"Lotery A, Xiao X, Zlatava G, Loftus J: Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007, 91: 1303-1307. 10.1136\/bjo.2007.116939.","journal-title":"Br J Ophthalmol"},{"key":"162_CR12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/archopht.125.9.1249","volume":"125","author":"G Soubrane","year":"2007","unstructured":"Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Mon\u00e8s J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF: Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007, 125: 1249-1254. 10.1001\/archopht.125.9.1249.","journal-title":"Arch Ophthalmol"},{"key":"162_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00019053-200826010-00006","volume":"26","author":"AF Cruess","year":"2008","unstructured":"Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF: Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics. 2008, 26: 57-73. 10.2165\/00019053-200826010-00006.","journal-title":"Pharmacoeconomics"},{"key":"162_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/00019053-200321030-00003","volume":"21","author":"J Bonsastre","year":"2003","unstructured":"Bonsastre J, Le Pen C, Soubrane G, Quentel G: The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics. 2003, 21: 181-190. 10.2165\/00019053-200321030-00003.","journal-title":"Pharmacoeconomics"},{"key":"162_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/bjo.2003.035279","volume":"88","author":"C Hopley","year":"2004","unstructured":"Hopley C, Salkeld G, Wang JJ, Mitchel P: Cost-utility of screening and treatment for early AMD with zinc and antioxidants. Br J Ophthalmol. 2004, 88: 450-454. 10.1136\/bjo.2003.035279.","journal-title":"Br J Ophthalmol"},{"key":"162_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ophtha.2003.05.030","volume":"111","author":"TW Olsen","year":"2004","unstructured":"Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER: Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology. 2004, 111: 250-255. 10.1016\/j.ophtha.2003.05.030.","journal-title":"Ophthalmology"},{"key":"162_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group","year":"1999","unstructured":"Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999, 117: 1329-1345.","journal-title":"Arch Ophthalmol"},{"key":"162_CR18","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351: 2805-2816. 10.1056\/NEJMoa042760.","journal-title":"N Engl J Med"},{"key":"162_CR19","first-page":"1508","volume":"113","author":"U Chakravarthy","year":"2006","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006, 113: 1508-1521.","journal-title":"Ophthalmology"},{"key":"162_CR20","first-page":"815","volume":"25","author":"CR Gonzales","year":"2000","unstructured":"Gonzales CR: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2000, 25: 815-827.","journal-title":"Retina"},{"key":"162_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","volume":"114","author":"DS Boyer","year":"2007","unstructured":"Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007, 114: 246-252. 10.1016\/j.ophtha.2006.10.045.","journal-title":"Ophthalmology"},{"key":"162_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0002-9394(03)00223-X","volume":"136","author":"Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups","year":"2003","unstructured":"Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups: Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration--TAP and VIP Report 1. Am J Ophthalmol. 2003, 136: 407-418. 10.1016\/S0002-9394(03)00223-X.","journal-title":"Am J Ophthalmol"},{"key":"162_CR23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1242\/dev.125.9.1591","volume":"125","author":"LE Benjamin","year":"1998","unstructured":"Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998, 125: 1591-1598.","journal-title":"Development"},{"key":"162_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1126\/science.301.5632.452","volume":"301","author":"J Marx","year":"2003","unstructured":"Marx J: Angiogenesis: A boost for tumor starvation. Science. 2003, 301: 452-454. 10.1126\/science.301.5632.452.","journal-title":"Science"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-10-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-10-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-10-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-10-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:48:08Z","timestamp":1630468088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-10-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-10-2","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,9]]},"assertion":[{"value":"17 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"2"}}